Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CT1 DAP001/DSP 1083

Next Previous
Drug Profile

CT1 DAP001/DSP 1083

Alternative Names: Allo iPS cell-derived dopamine neural progenitor; Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells; CT1-DAP001; CT1-DAP001/DSP-1083; DSP-1083

Latest Information Update: 07 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sumitomo Dainippon Pharma
  • Developer Sumitomo Pharma
  • Class Induced pluripotent stem cell therapies; Neural stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Parkinson's disease

Most Recent Events

  • 18 Dec 2024 Phase-I clinical trials in Parkinson's disease in USA (Intracerebral) (NCT06753331)
  • 28 Apr 2023 Sumitomo Pharma plans a clinical study for Parkinson’s disease in USA in 2023
  • 29 Jul 2022 Sumitomo Pharma plans a clinical trial for Parkinson's disease in USA (Sumitomo Pharma, Financial report Q1 FY2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top